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410Impact of ethnicity on the natural history
of Parkinson disease
Anna Sauerbier1,2, Azman Aris1,2, Ee Wei Lim1,2,3, Kalyan Bhattacharya4, K Ray Chaudhuri1,2Summaryarkinson disease (PD) is a multifactorial and multisystem
condition;1 its heterogeneity manifests in the spread of  Parkinson disease (PD) affects people of all races and
ethnicity worldwide.
 PD is a multineurotransmitter and multisystem disorder and
our current concept of the natural history of PD has changed
considerably over the past decades.
 Many aspects of this heterogeneous condition still remain
unexplained; one aspect that is poorly studied is the role of
ethnicity and manifest motor and non-motor PD.
 Some preliminary data suggest that the prodromal risk of
developing PD, clinical symptom expression and the
experience of living with the condition may vary between
different ethnic groups.
 Several factors might play a role in the inﬂuence of ethnicity on
PD, such as pharmacogenetics, sociocultural aspects and
environmental exposures.
 Increased knowledge on the role of ethnicity in PD may help
shed light on the symptom expression and treatment
response of PD, address inequalities in health care delivery
worldwide and improve the delivery of personalised medicine.P neurotransmitter involvement, the wide range of evident
motor and non-motor symptoms with possible subtypes, and the
complex time line of PD, including a prodromal, motor and
palliative phase.2 PD affects people of all races and ethnicities
worldwide. The epidemiology of PD among various ethnic groups
has been poorly studied and the data arising have been contra-
dictory, with a suggestion that PD is relatively more frequent
in Western populations.3,4 However, systematic surveys do not
conﬁrm this observation, and local studies have suggested
that Asian and African people may express phenotypic variants of
PD.5-7 In addition, there have been reports of ethnic variation in
the frequency of known PD genes, including leucine-rich repeat
kinase 2 (LRRK2) and glucocerebrosidase (GBA).8
As an analogywith other neurological conditions, such as essential
tremor,9 multiple sclerosis10 and amyotrophic lateral sclerosis,11
differences between ethnicities have been reported in prevalence,
incidence and clinical presentation. Ethnic differences are
therefore important to explore, as this might improve awareness
of these conditions in underserved communities and address
inequalities in health care delivery worldwide.12,13
Our review aims to summarise some key studies emphasising the
importance of research investigating ethnicity and PD. We used
PubMed to analyse original and review articles, and specialist
society publications and guidelines for PD to formulate an
evidence-based overviewof the topics as applied to clinical practice.
Prevalence of Parkinson disease across different
geographical regions and ethnic groups
The origin of PD is thought to be multifactorial, including a
combination of important aspects such as genetics and environ-
mental factors (eg, neurotoxins and nutrition).14 Sociocultural and
geographical differences may inﬂuence nutrition and environ-
mental issues between different ethnicities. Therefore, it is not
surprising that the prevalence of PD has been suggested to vary
between different ethnicities across the world. However, the cur-
rent data are inconclusive and it is challenging to compare epide-
miological studies because the applied diagnostic criteria, case
ascertainment, sample sizes and methodology vary widely
between studies.4,15 Further, the varying age distribution, life
expectancy and length of survival worldwide might inﬂuence the
reported differences.4,16 These confounding factors have to be
taken into considerationwhen interpreting epidemiological data.17
The major approaches for epidemiological studies used in the
literature are:
 community based;18
 random cohort sample;19
 cross-sectional prevalence studies;20
 door-to-door survey;211 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK. 2Parki
London, UK. 3National Neuroscience Institute, Singapore. 4RG Kar Medical College and H database mining (questionnaires sent out to population);22
 death certiﬁcates;23
 drug tracer approach (registered levodopa prescriptions);24
 hospital admissions;25
 recipients of health care;26
 record-based general hospital;27 and
 post mortem survey.28
In 2007, Dorsey and colleagues29 estimated that the number of PD
cases worldwide is set to double by 2030, of which a large part is
related to the improved diagnosis in Asian and African countries.
Currently available literature indicates that the prevalence of PD
appears to be higher in the Western population compared with
Asians and Africans.3,4,13 Wright Willis and colleagues30 have
conducted a population-based study in Medicare beneﬁciaries
aged over 65 years in the United States and came to the same
conclusion that PD is more common in white people (overall age-
standardised prevalence, 2168/100 000) compared with black
people (1036/100 000) and Asians (1139/100 000).30 In addition, a
review by Pringsheim and colleagues17 analysed door-to-door
surveys and random population samples according to
geographic location published from 1985 to 2010. Their ﬁndings
showed that PD prevalencewas generally lower in Asia (including
India, Taiwan, Hong Kong, Korea, China, Japan, Singapore and
Saudi Arabia) compared with North America (Canada), Europe
(including France, Italy, Spain, the Netherlands and Germany),
Australia and South America (including Brazil, Uruguay,
Argentina and Bolivia). The authors found a signiﬁcant difference
for the population aged 70e79 years between Asia (646/100 000)
and North America, Europe and Australia (1601/100 000).nson’s Foundation Centre of Excellence, King’s College Hospital NHS Foundation Trust,
ospital, Kolkata, India. annasauerbier@nhs.net j doi: 10.5694/mja17.01074
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411However, there is a substantial variability in reporting among the
speciﬁc studies, even in each country, and several authors have
questioned if it can be generalised that the prevalence is lower in
Asian compared with Western populations.31 As an example,
in China, several studies have reported similar PD prevalence
compared with Western countries with dominantly white popu-
lation.32 Surathi and colleagues33 have argued that, in a diverse
country such as India, the prevalence cannot be generalised from
small population studies within India.33 In relation to differences
within Europe, a community survey-based study in Europe
(EUROPARKINSON Collaborative Study), including France,
Italy, the Netherlands and Spain, has concluded that there appear
to be no signiﬁcant differences in PD prevalence among countries
in Europe in spite of environmental differences.15 Therefore, more
large scale, multicentre epidemiological studies are needed to
ascertain true differences in prevalence.
Most studies agree that the prevalence increases with age
irrespective of the ethnic and geographical background.15,34,35
There is a clear tendency in an increase of life expectancy across
the world, which is likely to lead to a growth in disorders such as
PD and, thus, inﬂuence a change in the currently reported ﬁgures
worldwide.29,36 Moreover, several researchers have recently sug-
gested a different concept of PD, describing it as a syndromic
condition, not as a single disease.2,37-39 The syndromic multifocal
nature of PD is evident in the phenotypic heterogeneity of PD in
various ethnic groups, which we discuss below.
Description of atypical parkinsonism worldwide
In our review, we are considering different terminology. Atypical
parkinsonism refers to the atypical presentation of PD, different to
other well described types of parkinsonism, such as multiple
system atrophy, progressive supranuclear palsy and Lewy
body dementia. These atypical forms of parkinsonism are often
referred to as unclassiﬁable atypical parkinsonism. There are
several descriptions of these atypical presentations worldwide
which appear to vary between different ethnic groups and, there-
fore, it is an important aspect when discussing ethnic differences
in parkinsonism. Further, understanding of these unclassiﬁable
atypical parkinsonisms may help to better understand variations
between idiopathic PD in the future.
An occurrence of a three- to four-fold increase in the frequency of
atypical parkinsonismwas reported in Afro-Caribbean and Indian
ethnic minorities living in the United Kingdom.5 These atypical
features, characterised mainly by levodopa hypo-responsiveness,
bradykinesia dominance and early cognitive dysfunction, were
noticed even after the exclusion of clinically probable multiple
system atrophy, progressive supranuclear palsy and Lewy
body dementia. Chaudhuri and colleagues5 acknowledged that,
although the observation could only be validated with post
mortem conﬁrmation, it may nevertheless indicate increased
susceptibility of these ethnic groups to atypical parkinsonism,
secondary to different genetic make-ups and environmental
exposure before migration. The ﬁndings were later further ana-
lysed through imaging studies by subjecting the same cohort to
magnetic resonance imaging and 18F-ﬂuorodeoxyglucose and
18F-ﬂuorodopa positron emission tomography of the brain.40 In
spite of the atypical clinical presentation, the analysis showed
no difference between atypical and typical parkinsonism groups
and was suggestive of a pattern of idiopathic PD.
Similar ﬁndings were also reported in the French West Indies
population, where researchers and health professionals found a
clinical presentation of an atypical parkinsonism that could not beclassiﬁed as multiple system atrophy, progressive supranuclear
palsy or Lewy body dementia among local non-white patients.6,41
Reports from Guadeloupe describe a high prevalence (around
two-thirds) of atypical parkinsonism with levodopa hypo-
responsiveness.6 The phenotype was further characterised by
bradykinesia and rigidity dominance and absence of levodopa
peak-dose dyskinesia.6
It has been speculated that an environmental neurotoxic origin,
which may be associated with the increased consumption of
tropical teas and fruits of the Annonaceae family,6,42 may be one of
themain underlying risk factors for the high prevalence of atypical
forms of parkinsonism.
Worldwide, there are examples of atypical forms of parkinsonism
most likely due to an environmental factor. In Guam, for instance,
there were reports of an exceptional high prevalence of an “over-
lap” syndrome presenting with parkinsonism and motor neuron
disease and/or dementia. In 1956, this unclassiﬁable parkinsonism
was titled amyotrophic lateral sclerosis/parkinsonism-dementia
complex.43-46 A similar phenotype has also been reported on the
Kii peninsula, in Japan, and Papua, in Indonesia.47-49 Likewise, a
one-year study conducted in New Caledonia reported an unusu-
ally high prevalence of atypical parkinsonism, described by
bradykinesia and rigidity dominance, levodopa unresponsive-
ness, early dementia with frontal lobe signs and postural disor-
der.50 As a further example, mainly in Eastern Europe, there were
reports of another atypical parkinsonian syndrome (characterised
by bradykinesia, dysarthria, dystonia, postural impairment and
levodopa hypo-responsiveness) that was caused by intravenous
use ofmethcathinone hydrochloride (ephedrone), which contains
manganese.51Ethnicity and expression of motor and non-motor
symptoms in Parkinson disease
Symptom expression in PD is very heterogeneous. Besides motor
symptoms, the modern concept of PD encompasses non-motor
symptoms (NMS) as one of the main burdens and the key
determinants for the quality of life of patients with PD and their
carers.52 NMS have been increasingly studied during the past
decades, and it has been shown that they vary to a large extent
among patients, ranging from gastrointestinal and urinary to
cognitive problems. At present, there are tools to capture NMS in
a holistic manner, such as the patients’ self-reported NMS
Questionnaire (NMSQuest) or the health professional-completed
NMS scale.52 The validated NMS scale rates frequency and
severity and has been used to ascertain the occurrence of NMS in
a wide variety of PD cohorts, although largely in the white
population.52
A literature survey of NMS in Asian countries found that a high
prevalence of NMS was noticed across all the ethnic groups.53
Further evidence shows that between 90% and 100% of patients
report at least oneNMS, irrespective of their ethnic background, be
it white, Asian, Middle Eastern or African.3,53-56
Reports fromanother study involving the validation of theChinese
NMS scale revealed that the scale’s total score was 31.06  30.88 in
Asians57 versus 56.46  40.66 previously reported in white
people.52 However, these differences were also attributed to
different basic demographic data, such as age, disease duration
and motor stage (ie, Hoehn and Yahr stage58).57 Other studies in
Asia (with similar mean age, mean disease duration and median
Hoehn and Yahr stage) showed amuch higher burden, which was
133.2  47.5.59 In Tunisia, the validation study of the Arabic
Factors that may explain variability of clinical phenotype and
natural history observed in Parkinson disease across
different ethnicities6,53,81
 Life expectancy and length of survival with Parkinson disease
 Comorbidities
 Diet/nutritional status
 Cultural differences and beliefs
 Sociocultural habits
 Sociodemographic habits
 Perception of race/ethnicity concept
 Pharmacogenetics
 Other environmental issues
 Local guidelines, access and approach to (specialised) care and
treatment
 Pharmacoeconomics and social factors (inequalities of health care)
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412version of the NMS scale reported a mean NMS scale total score of
82  56.60 In conclusion, it appears thatNMSburden assessedwith
the NMS scale is high across all ethnic groups. More detailed
conclusions might only be drawn after further prospective
comparative controlled studies.53
Factors that may affect ethnic differences in
Parkinson disease
Several factors have been described and explored in order to
attempt explanations for the possible impact of ethnicity on PD.
Branson and colleagues61 highlighted the wide range of inﬂu-
encing factors that have to be taken into account. In their recent
review, they showed that there were reports of racial disparities in
most aspects of PD, from knowledge of the disease to diagnosis
and, ﬁnally, treatment.61
Firstly, variations between ethnic groups are evident when
considering comorbidities — with a higher rate of diabetes
among the Asian population62 — but further research is
required to establish whether this difference in comorbidities
inﬂuences the symptom expression of PD. In addition, dietary
habits have been suggested to be different across ethnic groups
and may also play a role.49,54,59,63 As an example, the Medi-
terranean diet has been associated with a decreased rate of
manifest PD,14,64 while the frequent consumption of raw vege-
tables has been associated with an increased rate, according to a
study in Hong Kong.65 A recent review has summarised
the possible connection between nutrition and neuro-
degeneration discussing possible underlying mechanisms, such
as an inﬂammatory process.14
Moreover, cultural differences and beliefs might be inﬂuencing the
observeddifferences among ethnic groups— several othermedical
conditions have addressed beliefs and signiﬁcant differences have
generally been reported.34 For example, one study reported that
African Americans and Chinese Americans perceived parkinso-
nian symptoms as a part of normal ageing, predisposing them to a
delay in diagnosis and treatment and, thus, to poorer clinical out-
comes.66 A study in cognitive decline has shown that, in some
cultures, cognitive decline might be regarded as something that
should be kept private, which may also be applicable to PD and
may inﬂuence the reporting and expression of symptoms in a
clinical setting.67
Further, race and ethnicity are concepts that are often applied in
different contexts; these concepts changed over time and there exist
large differences in culture and genes within one ethnic group.67
Genetic differences across ethnic groups also need to be consid-
ered. It has been suggested that various genetic mutations play a
role in observed differences across ethnic groups, including fre-
quency and clinical presentation of PD,68 and that the contribution
of several genetic factors is different between ethnicities.69 In spite
of the prevalence of a genetic mutation, it might not necessarily
translate into the same clinical expression across all ethnic
groups,12 which has to be further clariﬁed in the context of PD. As
an example, to date, different frequencies of variants of the LRKK2
gene have been associated with the risk of developing PD in a
varying population. The G2019S variant appears to be commonly
found inNorthAfricanArab andAshkenazi Jewish patients, while
the G2385R and R1628P variants are found more commonly in
selected Asian populations.70 Varying carrier frequencies have
also been described for GBA mutation.71,72 While the GBA
N370S mutation is most commonly reported in Ashkenazi
Jewish populations and has been rarely reported in the Asian
population, the L444P mutations appear to be more frequent inAsians.72 In addition, the clinical expression of PD might vary
depending on the underlying mutation.73 For example, LRRK2
G2019S or R1628P mutation carriers have been reported to
present with increased lower extremity involvement at onset
and postural instability and gait difﬁculty.74 On the other hand,
GBA mutations have been linked to an increased NMS burden,
with higher degree of impaired cognitive function.75 How and if
these genetic mutations can be applied to ethnic differences is
currently unknown.
Variations in the catechol-O-methyltransferase enzyme, which
inﬂuences the rate of levodopa metabolism, have been
described in the literature, with a possible increased prevalence
of the variant that metabolises levodopa quicker among the
African population compared with white people.76 At least
partly, this variation might be associated with the described
differences in response to levodopa replacement therapy. In
addition, environmental factors should also be considered. So
far, aspects such as living in a rural area, well water use,
exposure to pesticides and heavy metals have been reported to
increase the risk of developing PD.67
Finally, it has been suggested that access and approach to
specialised treatment can vary considerably between different
ethnicities,34,77 including differences in insurance coverage,
quality of care, and inpatient behaviour, in particular, towards
help seeking and compliance. A delay in diagnosis and treat-
ment can have a dramatic negative impact on disease severity
and disability.78 In the United States, it has been shown that
patients from minority backgrounds receive lower quality of
care and have higher barriers to access treatment.79 Several
studies have reported a decreased number of referrals for deep
brain stimulation in African Americans compared with their
white counterparts.61
When investigating clinical symptoms and living with PD,
such as acceptance of the condition and family support, phar-
macoeconomics and social factors need to be considered.
However, new studies dealing with this complex problem are
lacking. The use of alternative medicine may also play a key
role. It has been shown that, for instance, in India, most
patients use traditional medicine, which might inﬂuence the
presentation of their parkinsonian symptoms.80 The Box sum-
marises the possible factors that may explain the variability of
clinical phenotype and natural history observed in PD across
different ethnicities.4
Narrative reviewFuture implications
To date, the role of ethnicity in PD is poorly understood and is a
very complex issue. Within these caveats, current literature pro-
poses that ethnicity has at least partly an impact on clinical
expression including motor and non-motor symptoms. In addi-
tion, there might be a link between ethnicity and pharmacoge-
nomics, presenting as different responses to drug treatment, as
exempliﬁed with the varying activity of the catechol-O-
methyltransferase enzyme. Further, there may be variability in
genetic expression among different ethnic groups which may
subsequently translate into clinical phenotypes (eg, GBA), since
such ethnic differencesmight inﬂuence the pathophysiology of PD
at least partly. However, what is currently available in the litera-
ture may not be truly representative. Moreover, it is difﬁcult to
compare currently available data because race and ethnicity have
not always been deﬁned consistently.12,82
We live in a global world, but our understanding and the
management strategy for PD are largely based on data on white
people. We are now aware that, contrary to previous beliefs, PD is
also common in non-white populations across the world. However,
robust clinical studies dealing with epidemiology, natural history,
clinical symptom expression andmanagement in these populations
are lacking.5 For example, the delivery of advanced therapies based
on non-oral strategies in PD remains an unmet need.In order to accurately investigate the incidence and prevalence of
PD worldwide and establish if there are actual differences across
ethnic groups, an inclusive and comprehensive global epidemi-
ological study is warranted. Such studywould allow the growing
need for management of the second most common neurodegen-
erative disease to be truly dealt with,61 which is also important for
the future development of public health services.12 By further
understanding the possible differences in PD across various
ethnic groups, researchers and clinicians may gain new crucial
insights into the underlying aetiologies, pathogenesis, expression
and treatment response of PD.12 Ethnic differences in pharma-
cogenetics, pharmacoeconomics and pharmacogenomics should
be considered by health professionals and policy makers in rela-
tion to the holistic management of a patient with PD, which
directly leads to the newly emerging concept of improved
personalised medicine.83
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